The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial

Allergic Diseases

Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial

Allergy

Zielen S, Bernstein JA, Sturm GJ, Jutel M, Pfaar O, RESONATE Investigator Group, Shamji MH, Mösges R, Berger M, Berger UE, DuBuske L, Layhadi JA, Klimek L, Ollert M, Skinner MA, Kramer MF, de Kam PJ

doi: 10.1111/all.16491

Atopic Dermatitis

Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Moderate to Severe Atopic Dermatitis in Adults and Children Down to 2 Years of Age in the Pivotal Phase 3 ADORING Trials

J Am Acad Dermatol

Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, Papp KA, Browning J, Kwong P, Korman NJ, Brown PM, Rubenstein DS, Piscitelli SC, Somerville MC, Tallman AM, Kircik L

doi: 10.1016/j.jaad.2024.05.023

Further Publications Dermatology

Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials

J Eur Acad Dermatol Venereol

Calabrese L, Cartocci A, Rubegni P, French LE, Kendziora B

doi: 10.1111/jdv.20617

Immunodeficiency

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis

Clin Immunol

Rao VK, Šedivá A, Dalm VASH, Plebani A, Schuetz C, Shcherbina A, Trizzino A, Zharankova Y, Orpia A, Kulm E, Webster S, Körholz J, Lougaris V, Rodina Y, Conlon N, Coulter T, Bradt J, Relan A, Uzel G

doi: 10.1016/j.clim.2024.110400

Further Publications Immunology

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Lancet

Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V, Beck HJ, Kerkhoff A, Unger B, Rank A, Schroers R, Zum Büschenfelde CM, de Wit M, Trautmann-Grill K, Kamper P, Molin D, Kreissl S, Kaul H, von Tresckow B, Borchmann S, Behringer K, Fuchs M, Rosenwald A, Klapper W, Eich HT, Baues C, Zomas A, Hallek M, Dietlein M, Kobe C, Diehl V, German Hodgkin Study Group, Swiss Group for Clinical Cancer Research, Arbeitsgemeinschaft Medikamentöse Tumortherapie, Nordic Lymphoma Group, Australasian Leukaemia and Lymphoma Group

doi: 10.1016/S0140-6736(24)01315-1

Atopic Dermatitis

Effectiveness of a nurse-led one-to-one education programme in addition to standard care in children with atopic dermatitis: a multicentre randomized control trial

Br J Dermatol

Barbarot S, Aubert H, Vibet MA, Leray M, Foureau A, Elan F, Menneron L, Stalder JF, Mazereeuw-Hautier J, Phan A, Droitcourt C, Bursztejn AC, Boralevi F, Chiaverini C, Raison-Peyron N, Lasek A, Misery L, Abasq C, Mallet S

doi: 10.1093/bjd/ljae111

Allergic Diseases

Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial

J Investig Allergol Clin Immunol

Majorek-Olechowska B, Slomskis T, Zollerová L, Martín I, Sánchez C, Gilaberte I, Arranz P, BILA-4021/PED Research Group

doi: 10.18176/jiaci.1003

Melanoma and Skin Cancer

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Lancet Oncol

Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM

doi: 10.1016/S1470-2045(24)00338-3

Further Publications Immunology

A Streamlined Strategy for Basophil Activation Testing in a Multicenter Phase III Clinical Trial

J Allergy Clin Immunol Pract

Suárez-Fariñas M, Grishin A, Arif-Lusson R, Bourgoin P, Matthews K, Campbell DE, Busnel JM, Sampson HA

doi: 10.1016/j.jaip.2024.09.007

Related content